Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Targovax ASA ( (GB:0RIS) ) has shared an announcement.
Circio Holding ASA has announced the conversion of NOK 2,500,000 worth of convertible bonds into 3,778,718 new shares, increasing its share capital by NOK 2,267,230.80. This move reflects the company’s ongoing financial strategy to support its innovative biotech ventures, including its circRNA platform and cancer vaccine development, with potential implications for its market position and stakeholder value.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing novel circular RNA gene therapies and immunotherapy medicines. It has created a unique circRNA expression platform, circVec, which is designed for efficient biogenesis of multifunctional circRNA from DNA and viral vectors. This platform aims to set a new standard for DNA and virus-based therapeutics. Circio is also working on a pan-RAS cancer vaccine, TG01, which targets KRAS driver mutations and is currently under clinical trials in the USA and Norway.
YTD Price Performance: 0%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: NOK54.97M
Find detailed analytics on 0RIS stock on TipRanks’ Stock Analysis page.
